Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.

Research Grants 20 show all


$199.3K
2012

$110.5K
2013

$999.5K
2014

$2M
2015

$538.8K
2016

Publications 16 show all

  • 3
    Bacterial Vaccines
  • 3
    Cholesterol Ester Transfer Proteins/immunology
  • 2
    Atherosclerosis/prevention & control
  • 2
    Chickens/microbiology
  • 2
    Oligosaccharides/chemistry
  • 1
    Adjuvants, Immunologic/administration & dosage
  • 1
    Adjuvants, Immunologic/genetics
  • 1
    Antigens, Bacterial/immunology
  • 1
    Aorta/pathology
  • 1
    Arteriosclerosis/drug therapy

Patents 489show all

  • 259
    A61K - Preparations for medical, dental, or toilet purposes
  • 221
    C07K - Peptides
  • 94
    C12N - Microorganisms or enzymes
  • 67
    Y02A - Technologies for adaptation to climate change
  • 34
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 28
    A01K - Animal husbandry
  • 24
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
  • 12
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 8
    A01N - Preservation of bodies of humans or animals or plants or parts thereof
  • 8
    C12Y - Enzymes

Clinical Trials 62show all

19Phase 117Phase 210Phase 1/Phase 28N/A5Phase 31Other

SEC Filings show all


171
8-K

75
10-Q

23
10-K

3
D

Contact Information

53 Frontage Road Suite 220
Hampton, NJ 08827
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$2,000,000101-2502014-10-24Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-10-24$2,000,000Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2014-10-24$2,000,000$2,000,000Equity
2003-07-21Unknown Unknown Other (Paper Filing)

Key Executives

  • Herbert J. Conrad
    Director
  • Larry Ellberger
    Director
  • George O. Elston
    Director
  • Karen Shoos
    Director
  • Anthony S. Marucci
    Executive Officer, Director
  • Harry H. Penner, Jr.
    Director
  • Timothy M. Shannon, M. D.
    Director
  • Avery W. Catlin
    Executive Officer